Incidence, Predictors, and Mid-Term Outcomes of Possible Leaflet Thrombosis After TAVR
- PMID: 28017712
- DOI: 10.1016/j.jcmg.2016.11.005
Incidence, Predictors, and Mid-Term Outcomes of Possible Leaflet Thrombosis After TAVR
Abstract
Objectives: This study sought to clarify the incidence and predictors of hypoattenuated leaflet thickening (HALT) and mid-term outcomes after transcatheter aortic valve replacement.
Background: HALT detected on multidetector computed tomography (MDCT) scanning raised concerns about possible subclinical leaflet thrombosis.
Methods: We studied 70 of 100 consecutive patients from a single-center registry who underwent implantation with the Edwards SAPIEN-XT device. MDCT results, echocardiographic data, and laboratory findings obtained at the 6-month and 1-year follow-ups were analyzed.
Results: Of 70 patients, MDCT scans revealed HALT in 1 patient (1.4%) at discharge, 7 (10.0%) at 6 months, and 10 (14.3%) at 1 year post-transcatheter aortic valve replacement cumulatively. The degree of leaflet immobility correlated with the HALT area on 4-dimensional MDCT (r = 0.68) on the basis of data from 10 patients. HALT was associated with male sex (70% vs. 25%; p = 0.008) and larger sinus of Valsalva (31.0 ± 2.0 mm vs. 28.6 ± 2.6 mm; p = 0.005). HALT was found in 3 of 49 patients with a 23-mm bioprosthesis and in 7 of 21 patients with a 26-mm bioprosthesis (6.1% vs. 33.3%; p = 0.006). D-dimer levels were significantly increased in the HALT group at the 6-month (2.3 μg/ml [interquartile range (IQR): 2.1 to 6.1 μg/ml] vs. 1.1 μg/ml [IQR: 0.8 to 2.2 μg/ml]; p = 0.002) and 1-year (2.7 μg/ml [IQR: 1.7 to 4.8 μg/ml] vs. 1.2 μg/ml [IQR: 0.9 to 2.1 μg/ml]; p = 0.006) follow-ups, despite no differences at discharge. The pressure gradient was decreased in the HALT group at the 1-year follow-up (8.3 ± 0.8 mm Hg vs. 11.1 ± 4.9 mm Hg; p = 0.005). After detecting HALT, additional anticoagulation therapy was not administered. Clinical outcomes, including all-cause mortality (0% vs. 1.7%; p = 1.00) and stroke (0% vs. 0%; p = 1.00), were similar between the groups.
Conclusions: HALT with reduced leaflet motion was not rare but usually subclinical. Valve hemodynamics and mid-term outcomes were uneventful even without additional anticoagulant therapy in our limited number of cases. Male sex, larger sinus and bioprosthesis size, and elevated D-dimer levels during follow-up were associated with this phenomenon.
Keywords: D-dimer; TAVR; aortic stenosis; reduced leaflet motion; thrombosis.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Transcatheter aortic valve thrombosis: the relation between hypo-attenuated leaflet thickening, abnormal valve haemodynamics, and stroke.Eur Heart J. 2017 Apr 21;38(16):1207-1217. doi: 10.1093/eurheartj/ehx031. Eur Heart J. 2017. PMID: 28369242
-
Natural History of Leaflet Thrombosis After Transcatheter Aortic Valve Replacement: A 5-Year Follow-Up Study.J Am Heart Assoc. 2022 Dec 6;11(23):e026334. doi: 10.1161/JAHA.122.026334. Epub 2022 Nov 29. J Am Heart Assoc. 2022. PMID: 36444836 Free PMC article.
-
Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves: PARTNER 3 Cardiac Computed Tomography Substudy.J Am Coll Cardiol. 2020 Jun 23;75(24):3003-3015. doi: 10.1016/j.jacc.2020.04.043. J Am Coll Cardiol. 2020. PMID: 32553252 Clinical Trial.
-
Gender Differences and Outcomes of Hypoattenuated Leaflet Thickening (HALT) Following Transcatheter Aortic Valve Replacement: A Meta-analysis of Randomized and Cohort Studies.Curr Probl Cardiol. 2023 Jul;48(7):101155. doi: 10.1016/j.cpcardiol.2022.101155. Epub 2022 Feb 19. Curr Probl Cardiol. 2023. PMID: 35192871 Review.
-
Hypoattenuated leaflet thickening (HALT) and reduced leaflet motion (RELM) of aortic bioprostheses: An imaging finding or a complication?Prog Cardiovasc Dis. 2022 May-Jun;72:78-83. doi: 10.1016/j.pcad.2022.05.007. Epub 2022 Jun 5. Prog Cardiovasc Dis. 2022. PMID: 35675882 Review.
Cited by
-
Altered blood flow due to larger aortic diameters in patients with transcatheter heart valve thrombosis.APL Bioeng. 2023 Dec 19;7(4):046120. doi: 10.1063/5.0170583. eCollection 2023 Dec. APL Bioeng. 2023. PMID: 38125699 Free PMC article.
-
Early 6 months usage of single anTiplAtelet OR anTicoAgulant followed by single antiplatelet after transcatheter aortic valve replacement: protocol for a multicentre, open-label, randomised controlled clinical trial.BMJ Open. 2023 Nov 21;13(11):e076781. doi: 10.1136/bmjopen-2023-076781. BMJ Open. 2023. PMID: 37989381 Free PMC article.
-
Leaflet thrombosis in transcatheter aortic valve intervention: mechanisms, prevention, and treatment options.Front Cardiovasc Med. 2023 Oct 6;10:1249604. doi: 10.3389/fcvm.2023.1249604. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37868777 Free PMC article. Review.
-
Platelet and Monocyte Activation After Transcatheter Aortic Valve Replacement (POTENT-TAVR): A Mechanistic Randomized Trial of Ticagrelor Versus Clopidogrel.Struct Heart. 2023 Apr 28;7(4):100182. doi: 10.1016/j.shj.2023.100182. eCollection 2023 Jul. Struct Heart. 2023. PMID: 37520136 Free PMC article.
-
A Contemporary Review of Antiplatelet Therapies in Current Clinical Practice.Int J Mol Sci. 2023 Jul 5;24(13):11132. doi: 10.3390/ijms241311132. Int J Mol Sci. 2023. PMID: 37446310 Free PMC article. Review.
LinkOut - more resources
Full Text Sources
Other Literature Sources
